Targeted delivery of drug molecules to specific cells in mammalian systems demonstrates a great potential to enhance the efficacy of current pharmaceutical therapies. Conventional strategies for pharmaceutical delivery are often associated with poor therapeutic indices and high systemic cytotoxicity, and this result in poor disease suppression, low surviving rates, and potential contraindication of drug formulation. The emergence of aptamers has elicited new research interests into enhanced targeted drug delivery due to their unique characteristics as targeting elements. Aptamers can be engineered to bind to their cognate cellular targets with high affinity and specificity, and this is important to navigate active drug molecules and deliver sufficient dosage to targeted malignant cells. However, the targeting performance of aptamers can be impacted by several factors including endonuclease-mediated degradation, rapid renal filtration, biochemical complexation, and cell membrane electrostatic repulsion. This has subsequently led to the development of smart aptamer-immobilized biopolymer systems as delivery vehicles for controlled and sustained drug release to specific cells at effective therapeutic dosage and minimal systemic cytotoxicity. This article reports the synthesis and in vitro characterization of a novel multi-layer copolymeric targeted drug delivery system based on drug-loaded PLGA-Aptamer-PEI (DPAP) formulation with a stage-wise delivery mechanism. A thrombin-specific DNA aptamer was used to develop the DPAP system while Bovine Serum Albumin (BSA) was used as a biopharmaceutical drug in the synthesis process by ultrasonication. Biophysical characterization of the DPAP system showed a spherical shaped particulate formulation with a unimodal particle size distribution of average size 0.685 mm and a zeta potential of 10.82 mV. The DPAP formulation showed a high encapsulation efficiency of 89.4 6 3.6%, a loading capacity of 17.89 6 0.72 mg BSA protein/ 100 mg PLGA polymeric particles, low cytotoxicity and a controlled drug release characteristics in 43 days. The results demonstrate a great promise in the development of DPAP formulation for enhanced in vivo cell targeting.
Introduction
Conventional therapeutic delivery strategies for emerging drug systems and active pharmaceutical ingredients are predominately challenged with low efficacy resulting from poor pharmacokinetics, pharmacodynamics and specificity toward target cells. This can cause high systemic cytotoxicity and serious adverse effects amongst patients, and has encouraged the search for improved therapeutic delivery designs. Targeted drug delivery platforms are a viable approach for advanced in vivo cell targeting in medical diagnostics and therapeutic delivery applications. An effective drug design strategy would enable controlled and sustained delivery of active drugs with sufficient dosage to malignant sites over a desired period of time to achieve optimal therapeutic efficacy. In this study, we employed a DNA aptamer as the targeting element in the design of a novel co-polymeric drug carrier and navigation system, based on poly(lactic-co-glycolic acid) (PLGA) and poly(ethylene imine) (PEI) layered complexation, to enhance in vivo targeting of specific mammalian cells. Aptamers are made of single-stranded RNA or DNA oligonucleotides with about 20-50 nucleotides length, 1, 2 and are capable of folding into unique 3-D conformations to bind with their cognate targets via hydrogen bonding, Van der Waals, electrostatic, and hydrophobic interactions. 3, 4 Aptamers possess desirable biophysical and biochemical properties as a new class of targeting elements. These properties include high affinity and specificity toward target cells and biomolecules, small size for effective hydrodynamics and cyto-membrane penetrations, ease of generation and synthesis, ease of biochemical labeling and molecular formulation, and high chemical and thermal stability. 3, 5 The approval of the first aptameric biological drug, Pegatanib, in 2004 by U.S Food and Drug Administration (FDA) has incited significant research interests on the medical applications of aptamers. There are various aptamer-based drug designs undergoing clinical trials, and these include AS1411 nucleolin-specific aptamer for acute myeloid leukemia and REG1-targeting aptamer for coronary artery disease. 6 Despite the afore-mentioned desirable characteristics of aptamers as targeting elements, there are some challenges faced by aptamer-mediated drug delivery system for effective cell targeting. These limitations include endonuclease degradation of aptamer molecules, cell membrane electrostatic repulsion, undesirable biochemical complexation and immobilization, and rapid renal filtration of aptamer molecules. 7 The application of biopolymers as delivery carriers has, as a result, become an important strategy to circumvent the drawbacks of aptamer delivery. Compared to other delivery vectors such as viruses and bacteria, biopolymeric formulations are highly preferable for pharmaceutical and medical applications due to their safety and efficacy. They are also biodegradable, biocompatible, and nonimmunogenic. In addition, their tunable biophysical properties and the ease of surface modifications to couple bio-functional moieties to enable a controlled and prolonged drug release profile 8, 9 make them very attractive. Therefore, the use of polymeric particles encapsulating aptamers as targeting elements is a promising endeavor to advance and improve the delivery of sufficient drug dosage to specific target sites and achieve high therapeutic index for clinical treatments. 10 Several research reports have demonstrated the potential of aptamer-conjugated polymeric particles to enhance the therapeutic effects of biological drugs to treat breast cancer, 10, 11 prostate cancer, 12 leukemia, 13, 14 and colon cancer. 15 Biopolymers such as PLGA and PEI are FDA approved biodegradable and biocompatible polymers for pharmaceutical applications and they possess tunable characteristics such as particle size distribution, surface charge, pH-sensitive degradation kinetics, surface area, and low cytotoxicity levels. PLGA polymeric particles can encapsulate DNA molecules at high encapsulation efficiencies and provide a slow and sustained drug release with low cytotoxicity. 16 The effective performance of PLGA as a delivery carrier has been demonstrated extensively. 10, 11, 13, 14, 17 Also, PEI is an effective drug carrier amongst other cationic biopolymers due to its high transfection efficiency and ability to condense negatively charged oligonucleotide via electrostatic interactions to form a stable polyplex for enhanced cellular uptake into target cells. 18, 19 Moreover, the proton sponge mechanism of PEI particles can facilitate enhanced endosomal release of encapsulated active drugs. 20 Several research studies have demonstrated the capacity of PEI as an effective carrier for targeted delivery. 18, 19 This research article reports a novel design strategy based on layered complexation process for the synthesis of a multifunctional drug carrier co-polymeric composite called DPAP formulation henceforth in this article. The DPAP formulation is composed of different compartments (a) bovine serum albumin (BSA) protein, acting as a drug model, |D|, (b) hydrophobic poly D, L-lactide-co-glycolic acid (PLGA) hydrophobic polymeric core encapsulating BSA, |P|, (c) thrombin-specific DNA aptamer conjugated onto the surface of PLGA, |A|, (d) hydrophilic (PEI) polymer outermost layer surrounding the BSA-PLGA-Aptamer core, |P|. To date, no research study has been reported on aptamer conjugated PLGA-PEI copolymeric system with this formulation design. The biophysical characteristics of the DPAP formulation were investigated by size and zeta potential measurements and morphological analysis, as well as and its efficiency as a targeted drug delivery system based on its in vitro loading capacity, encapsulation efficiency, drug release rate and systemic cytotoxic effects.
Methodology

Materials
PLGA acid (PLGA) with molecular weight 30,000-60,000 Da and 50:50 ratio of lactide:glycolide; Branched (PEI) with a molecular weight 25,000 Da; Poly(vinyl alcohol) (PVA) of molecular weight 31,000-50,000 Da (98-99% hydrolysed); 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide (EDC) with molecular weight 191,70 g/mol (commercial grade, premium quality level); N-hydroxysuccinimide (NHS) with molecular weight 217,13 g/mol (98% (HPLC); Acetone with 58.08 g/mol (Laboratory Reagent, 99.5%); and Phosphate buffered saline (PBS) tablets (one tablet dissolved in 200 mL deionized water at 258C yields 0.01 M phosphate buffer, 0.0027 M potassium chloride, 0.137 M sodium chloride, and pH 7.4) were purchased from Sigma Aldrich, Malaysia. Bovine serum albumin (BSA) with molecular weight 66,000 Da (98% by agarose electrophoresis) was purchased from Santa Cruz, USA. 15-mer thrombin specific-DNA aptamer, 5 0 -GGT TGG TGT GGT TGG-3 0 (5.0 mmole scale, PCR Grade, 225 OD) was purchased from 1 st BASE Malaysia.
Synthesis of DPAP particulate formulation
The DPAP formulation was synthesized using a water-inoil-in-water (w/o/w) double emulsion technique with sonication. 2% w/v BSA solution was prepared by mixing BSA with de-ionized water and 6.7% w/v PLGA was prepared by mixing PLGA with acetone to form a polymeric stock matrix. The BSA solution was transferred into the polymer stock and mixed thoroughly using an ultrasonic homogenizer (Labsonic R M, Sartorius Group, Germany.) at 70% amplitude, 0.7 s pulse cycle for 2 min to form the DP system. 2% w/v PVA solution was added to the DP mixture as a hardening agent to emulsify and produce DP emulsion droplets via sonication under the mentioned conditions. Subsequently, the organic solvent accompanying the emulsion was evaporated at room temperature by shaking gently for 2 h at 200 rpm. The mixture was centrifuged at 4,000 rpm and 48C for 20 min using a refrigerated centrifuge (Universal 320R, Hettich, UK) to remove residual organic solvent prior to freezedrying to produce solidified BSA-loaded PLGA particles (DP particles).
EDC and NHS activation chemistry. The thrombin-specific DNA aptamer was conjugated onto the outer layer of the DP particles by EDC and NHS activation chemistry. The DP particles were incubated in PBS buffer containing 400 mM EDC and 100 mM NHS for an hour with gentle shaking at 200 rpm followed by centrifugation at 4,000 rpm and 48C for 20 min. EDC enabled the coupling of carboxyl groups followed by NHS activation which replaced EDC with hydroxyl groups. This chemical coupling process is necessary to enhance electrophilicity to catalyse the formation of covalent amide linkages between the amine groups of DNA aptamer and the carboxyl groups of DP particles. The resulting NHS-activated DP-COOH complex was incubated with 100 mM aptamer for an hour at 200 rpm followed by centrifugation to enable aptamer conjugation for the generation of aptamer-DP particles (DPA). The DPA system was wash with de-ionized water and centrifuged for 20 min at 4,000 rpm and 48C repeatedly to eliminate unbound aptamer molecules. The resulting DPA conjugates particles were used to produce the DPAP formulation using the described synthesis protocol in section 2.2 using PEI polymer as the outermost polymeric layer that encapsulating DPA particles. 12% w/v PEI stock was prepared by mixing PEI with acetone, and 1% w/v DPA was added, and mixed thoroughly using ultrasonic homogenizer for 2 min. 2% w/v PVA solution was added to produce DPAP emulsion droplets prior to solvent evaporation and the system was incubated at room temperature for 2 h under 200 rpm. The mixture was then centrifuged for 20 min before freeze-drying to produce BSA-loaded PLGA-Aptamer-PEI particles (DPAP particles).
Biophysical characterization of DPAP formulation
Dynamic light scattering (DLS) analysis using Malvern Zetasizer Nano ZS, Model ZEN3600 (UK) was used to study the particle size distribution and zeta potential of each surface layer configuration during the synthesis of DPAP particles. The morphology and shape of the DPAP particles were examined using scanning electron microscopy (SEM) and transmission electron microscopy (TEM).
Chemical analysis of DPAP particles
Fourier transform infrared spectroscopy (FTIR) was used to identify various functional groups and chemical bonds in DPAP particles to identify any potential modifications in the initial compositional structures during the synthesis process. The principle of FTIR is based on relative spectral vibration of molecules in a sample on exposure to infra-red (IR) within a specific range of wave number or frequency. The IR spectra of DPAP was obtained in the frequency range 500 to 3,900 cm
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Determination of BSA and aptamer encapsulation efficiencies
The amounts of encapsulated BSA and aptamer within the DPAP particulate formulation were quantified as the difference between the initial amounts of BSA and aptamer applied during formulation and the amount of free BSA and aptamer detected in the PVA hardening agent after DP and DPAP composites formation. After the formation of DP composite, the DP suspension was centrifuged at 4,000 rpm and 48C for 20 min using a refrigerated centrifuge (Universal 320R, Hettich), and the free BSA in the supernatant was measured using a UVVisible spectrophotometer (Lambda 25 UV/Vis Double Beam, Perkin Elmer) at 260 nm. The free aptamer concentration in the supernatant was measured at 280 nm after centrifuging the DPAP suspension at 4,000 rpm and 48C for 20 min. All the measurements were repeated three times and averaged. The encapsulation efficiency and loading capacity were calculated using following equations:
Encapsulation efficiency % ð Þ5 Amount of encapsulated BSA or aptamer Amount of BSA or aptamer applied 3 100
Loading capacity 5 Amount of encapsulated BSA mg ð Þ Total PLGA added mg ð Þ
In vitro release profile
The release profile of BSA protein from the DPAP particulate formulation was investigated in a physiological PBS buffer system using an incubator shaker. 2% w/v concentration of DPAP particles in PBS buffer was incubated at pH 7.4, temperature 378C and speed 120 rpm. At designated time intervals (24 h intervals from day 1 to day 8; 72 h interval from day 9 to day 38; and 120 h interval from day 38 to day 43), the DPAP/ buffer mixture was centrifuged for 10 min at 4,000 rpm and 48C to form DPAP pellet, and the 5 mL supernatant was decanted for UV spectrophotometric analysis at 260 nm to determine the concentration of released BSA. The removed 5 mL supernatant was replenished fresh PBS buffer to re-suspend the DPAP pellet for continuous incubation.
MTS cytotoxicity assay
MTS cytotoxicity assay is a type of proliferation assay that uses a colorimetric method to quantify viable cells. Chinese hamster wild-type cell line V79B cells were cultured in a 96-well microtitre plate to obtain 5 3 10 3 cells/well using a 10% fetal bovine serum supplemented DMEM media in a humidified CO 2 incubator at 37 6 28C and 5 6 1% CO 2 for 24 6 2 h to allow cell attachment. The V79B cells were incubated with the DPAP particles at 6 different concentrations: 0.15625, 0.3125, 0.625, 1.25, 2.5, and 5 mL/mL to a final volume of 6 mL of each. 200 mL of each treatment was pipetted into selected wells and DPAP sample solution without cells was used as the blank. The plate was then incubated for 24 h 6 30 min at 37 6 28C and 5 6 1% CO 2 in the CO 2 incubator. After 24 h 6 30 min incubation, 40 mL of MTS reagent was added into each well. Subsequently, the plate was incubated for an hour in the CO 2 incubator. After the 1 h incubation, the plate was analyzed with ELISA plate reader at 492 nm. With this assay, a sample is considered cytotoxic if the cell viability is equal or less than 50%. 21 
Results and Discussion
Effect of pH on the hydrodynamic size and surface charge of BSA Figure 1 shows that the average D [4, 3] hydrodynamic size of BSA molecule under varying pH conditions of pH 3 to 11 generally ranged from 8.6 to 14.60 nm with a polydispersity index (PdI) of 0.3, except pH conditions 4 and 7 which showed an average hydrodynamic size of 58.2 nm and 229.5 nm respectively. The pH effect on hydrodynamic size distribution is the result of surface electrical charge accumulation and stability in response to protonation and deprotonation of the protein molecule. At the isoelectric point (IEP) of BSA, both the inter-chain electrostatic repulsive forces and excess charge density of the molecule are reduced to zero, and this results in a higher inter-chain aggregation. The results showed BSA IEP of 4.31 under the experimental conditions. At the IEP, the protein possesses a net charge of zero with minimal intermolecular repulsive forces, and this causes the structure of the protein to be less stable and more hydrophobic. As a result, the protein molecules tend to aggregate and precipitate with minimum solubility. 22 Charge accumulation and neutralization can also result in changes in the 3D structure of the protein and affects the spatial orientation in solution and the degree of thermal entropy required to achieve molecular stability. 23, 24 The IEP of BSA in aqueous solutions have previously been reported to vary, 25, 26 mostly from 4.2 to 5.7. The variation in the IEP values is due to potential interference with native ionic groups associated with the buffer environment, the use of different measurement techniques, and physicochemical conditions of the buffer/protein system in terms of purity, temperature and ionic conductivity. 22 At pH 4, the average hydrodynamic size of BSA molecules peaked at 58.2 nm due to the close proximity to the IEP of BSA, resulting in increased protein-surface interactions, reduced repulsive interaction between protein molecules and increased hydrodynamic size. [25] [26] [27] Under this condition, the protein conforms to a characteristic slow migration nature with a higher protein maximum dimension and asymmetry. 25, 28 BSA has been reported to have various pH-dependent conformations and its normal form is in the pH range 4.5 to 7.0. 25 At pH 7, BSA showed a maximum size of 229.5 nm. This protein size enlargement of more than 25% is due to the introduction of large surface charge density of the protein molecule with increased hydrophobic interactions and intramolecular repulsion, resulting in unfolding of the protein tertiary structure and irreversible protein aggregation. 25, 27 Further increase in pH showed basic conformational transition of BSA molecules that normally occurs between pH 8 to 9. Consequently, the protein loses rigidity and affects the amino-terminal and ligand binding regions. 25, 28 Around pH 10, BSA will gradually transit into aged forms with reduced tertiary contacts, and then become cleaved at pH > 10.5. 28 The average hydrodynamic size of BSA increased slightly as pH increased. This is expected as at low pH, BSA biomolecules are coil-like and are slowly converted into hard spheres as pH increases. 26 Zeta potential measurements indicate biomolecular stability facilitated by the degree of repulsion between adjacent molecules in a dispersion. 22 The surface charge and stability of protein molecules are influenced by pH due to amino acid dissociation balance. 26 The results showed that BSA demonstrated positive zeta potential at low pH, and decrease from 112.90 mV to 222.80 mV with increasing pH from 3 to 11. This decrease in zeta potential is due to charge deprotonation with increasing hydroxide ion concentration. Zeta potential of proteins is generally affected by molecular denaturation, aggregation, conformational structural changes, and surface modifications. 25 Effect of pH on the hydrodynamic size and surface charge of thrombin-specific DNA aptamer As shown in Figure 2 , changing the medium pH from 3 to 9 steadily increased the electronegativity of the thrombinbinding aptamer from 25.97 mV to 212.5 mV with a significant increase to 220.8 mV at pH 10 and 238.5 mV at pH 11. The average D [4, 3] hydrodynamic size of the aptamer was lowest at pH 3 (239.8 nm) and pH 11 (291.0 nm), potentially due to denaturation of DNA. The isoelectric point (IEP) of the aptamer was determined as 2.41. Hence, for in vivo applications and drug delivery, the net surface charge of the aptamer is negative. The thrombinspecific binding aptamer used in this work is a short DNA oligonucleotide, and demonstrates fairly stable surface charge and average hydrodynamic size characteristics over a broad pH range from 4 to 9 according to Figure 2 . DNA aptamer is made up of hydrophobic purines and pyrimidines which are water-insoluble at around pH 7. However, under moderate acidic or alkaline medium conditions, the surface charge of the purines and pyrimidines groups are altered to enhance solubility in aqueous systems through hydrolysis of DNA phosphodiester bonds. The degree of hydrolysis and the potential effect on DNA solubilization is minimal around pH 7. Under extreme alkaline pH conditions, high concentrations of hydroxide ions are present in the media, resulting in a nucleophilic attack of the aptamer phosphorus moieties and eventual hydrolytic cleavage of phosphodiester bonds. Consequently, the DNA oligonucleotide is degraded or denatured into smaller DNA fragments and this explains the reduced hydrodynamic size of the aptamer at pH 11. The size of the aptamer was also small under extreme acidic pH of 3. Strong acidic conditions can lead to purine protonation as well as cleavage of DNA b-glycosidic bonds between purine bases and phosphodiester bonds into nucleotides and nucleosides. 29 The variation in polydispersity index with pH change is due to the relationship between electronegativity, surface charge stability and overall impact on homogeneous molecular aggregation. Polydispersity indices under alkaline conditions were generally higher than those of acidic conditions. This is due to increasing electronegativity of the aptamer molecules and associated intermolecular repulsion, resulting in the generation of more stable and uniform individualized molecules with reduced tendency to form aggregates having a nonuniform size distribution.
DPAP design concept and degradation mechanism
To synthesis DPAP particles for targeted drug delivery, an integrated water-in-oil-in-water (w/o/w) double emulsion and sonication method was used. Compositionally, the DPAP particulate formulation was made up of a hydrophobic PLGA polymeric core entrapping BSA as a protein drug. Thrombinspecific DNA aptamer molecules were conjugated onto the surface of the PLGA polymeric core, and the outermost layer was glazed with a cationic polymer (PEI) particles surrounding the inner aptamer-conjugated BSA-loaded PLGA particles via electrostatic interactions with the aptamer layer to produce the DPAP system as shown by the schematic drawing in Figure 3 . The DPAP particulate is designed to present multifunctional characteristics where both PLGA and PEI biopolymers act as delivering vectors and carrier for the drug and aptamer. Figure  3 shows the design and synthesis of the DPAP particulate system starting from BSA encapsulation within PLGA particles to protect its functional and structural integrity, then the conjugation of aptamer onto the PLGA surface, and finally the entrapment of DPA particles within the PEI outermost layer to maintain the binding properties of the aptamer for enhanced target cell recognition, interaction, and delivery efficiency. The outer polymeric particulates, made up of cationic PEI, promote a positively charged DPAP polymeric surface to improve the binding of receptors onto target cells and endocytosis. This design concept is capable of shielding the entrapped protein drug and aptamer more effectively from premature release, degradation and undesirable biochemical complexation with bio-actives from physiological environment. Thus, problems associated with low drug dosage, poor drug biochemical integrity, protease and/or endonuclease degradation, as well as reduced targeting and binding affinity of the aptamer can be significantly reduced. Consequently, a more sustained and controlled drug release characteristics with enhanced pharmacokinetics and therapeutic index can be achieved. Figure 4 demonstrates the in vivo degradation mechanism of the DPAP particulate system in targeted drug delivery. The cationic PEI outermost layer tends to bind any negatively charged cell membranes due to electrostatic attractions. However, with the presence of intercalated aptamers within the PEI particles as the targeting elements, the binding activity of the PEI is site-directed, making the DPAP binding specific to target cell surface receptors or protein markers on target cells. The outer layer PEI and aptamer complex acts synergistically via condensation of the aptamer by cationic PEI particles with high transfection efficiency and the reduction of electrostatic repulsion to facilitate the migration of electronegative aptamer molecules to negatively charged target cell membrane thus, triggering internalization. Internalization, also called receptor-mediated endocytosis, promotes enhanced target cell uptake. 10, 30 Within the target cell, amine moieties associated with PEI are protonated and this results in counter-ion influxion and reduced osmotic potential. The PEI polymeric layer, as a result of osmotic imbalance, swells and bursts to release the encapsulated aptamer and the drug-loaded PLGA (DP) particles. The low pH environment of the endosome induces PLGA hydrolysis through the cleavage of ester bonding within its chain. This leads to gradual water uptake into the PLGA particulate matrix, resulting in swelling followed by degradation of PLGA to release the encapsulated drug molecule. 31, 32 The accumulation of PLGA monomers (lactic and glycolid acids) continues to lower the local pH, leading to autocatalyic ester hydrolysis for more drug release. 32 The released drug molecules diffuse into the cytosol and move toward the nucleus to induce therapeutic effects as highlighted in Figure 4 . Layer-by-layer hydrodynamic size analysis of DPAP particulate system DLS analysis using Malvern Zeta-sizer Nano was conducted to investigate the zeta potential, hydrodynamic size distribution and the colloidal stability of the different layered compartments of the DPAP system as well as cumulative effects on the biophysical properties on the final DPAP formulation at pH 7. The D [4, 3] average hydrodynamic diameter of the inner DP particulate layer was 1,059 nm, representing an increase from 229.5 nm for naked BSA upon successful encapsulation of BSA by PLGA polymeric particles. After EDC/NHS coupling reaction, the pH of the DP solution was adjusted to 2.7 to activate the surface charge of DP particles for enhanced electrostatic conjugation of the aptamer molecules. DLS results in Table 1 indicated that both EDC/NHS coupling and pH adjustment did not significantly alter the hydrodynamic size of DP particles. The hydrodynamic size of the formulation reduced to 1,217 nm after successful conjugation of aptamer molecules onto the surface of DP particles to form DPA particulate system. This hydrodynamic size reduction is due to electrostatic interactions between negatively charged aptamer molecules and positively charged DP particles, resulting in partial condensation of the particulate system. DLS analysis of the final DPAP formulation supported successful intercalation of PEI on the outer aptameric membrane of the DPA microenvironment to form DPAP formulation. This is due to the significant reduction in size of the DPAP formulation; from 1,217 nm for DPA to 685.6 nm for DPAP. This demonstrates that the outmost cationic PEI polymeric layer electrostatically interacted with and the condensed negatively charged DNA aptamer, resulting in the formation of stable intercalated polyplexes. Furthermore, the negatively charged DNA aptamer facilitated the stabilization of the PEI polymeric layer by creating a surface network configuration with reduced positive charges to generate particulate formulation with improved size homogeneity.
Biophysical characterization of DPAP particulate system
The BSA loaded PLGA-Aptamer-PEI particulate system was formulated by water-in-oil-in-water (w/o/w) double emulsion method integrated with sonication. The D [4, 3] average diameter of the DPAP particles was 0.686 mm with a zeta potential was 10.82 mV. The average particle size of the formulation is essential to promote effective DPAP-cell membrane surface interaction and intracellular trafficking. The measured average particulate size of the DPAP formulation is within the range effective to increase in vivo half-life of both drug and aptamer 13 and also prevent aptamers and drug-loaded polymeric particles from systemic clearance and rapid renal filtration, which is typically challenging for small size biomaterials with molecular weights within the range of 30-50 kDa. 7, 33 Compared to nanoparticles, microparticles are easier to be phagocytized by human phagocytic immune cells in vaccine delivery applications. 34, 35 The low electropositive potential of the DPAP formulation is result of the intercalation between the aptamer and the PEI system and this is necessary to enhance cell membrane interactions whilst simultaneously enabling specific targeting of disease cells for endocytosis. Figure 5 shows the particle size distribution of the DPAP formulation with a z-average of 685.5 nm. The distribution shows two different peaks: peak 1 with 593.4 nm size, 92.7% intensity and 265.6 nm standard deviation; and peak 2 with 5,368 nm size, 7.3% intensity and 329.6 nm standard deviation. The high peak 1 intensity of 92.7% demonstrates that the size distribution of DPAP is largely unimodal. The emergence of peak is highly due to agglomeration of DPAP particles facilitated by inter-particulate collision of DPAP droplets during solvent evaporation. The distribution also showed a polydispersity index of 0.49, indicating a narrow size distribution of the formulation. The polydispersity index also shows desired levels for improving drug delivery efficiency in term of tissue distribution and blood circulation duration. 10 The morphological characteristics of DP and DPAP microparticles were investigated via SEM and TEM analyses. The micrographs showed the shape of both DP (Figures 6 and 8a ) and DPAP (Figures 7 and 8b ) micro-particles were spherical with moderately rough surface features and small particles pore to improve cell-particle interactions. DP and DPAP particulate systems showed uniform dispersion. The average particle size of DP ranged from 279 nm to 1,200 nm whilst DPAP was between 860 nm and 1,300 nm based on TEM and DLS analysis. The microsphere morphologies of DP and DPAP formulation were similar, and this demonstrates that the incorporation of PEI did not significantly change the surface properties of DP particles. TEM images in Figure 8 reveals that the particle size and volume of DPAP were significantly larger than DP, indicating successful conjugation of DNA aptamer onto DP surface and PEI intercalation on the outermost layer. The average particle size of DPAP, which is < 2 mm, would facilitate a significant number of internalized DPAP particles into target cells to improve drug delivery due to its effective surface area for phagocytosis and endocytosis. 36 Particle size and shape play a significant role in formulating and delivering drugs to target cells for improved transfection and enhancing therapeutic efficiency. Microparticle formulations have been reported to protect DNA aptamers from endonuclease-mediated degradation, kidney filtration, and also provide an efficient delivery of aptamers to target cells.
10,16
The rough surface morphology of DPAP is important for effective surface modifications, making it easy for conjugation with other targeting elements and biomarkers to enhance transfection. 16 Functional group characterization of DPAP particulate system FTIR analysis was used to investigate the structural characteristics, chemical composition and functional groups present in the DPAP formulation. This analysis was important SEM analysis was performed at 10 kV over a magnification of x3,000 to x20,000. to identify potential in-process molecular derivatization of active moieties associated with the biopolymers during formulation. The FTIR transmittance spectra in Figure 9 identifies functional groups within the wave number range 3,900 to 500 cm 21 The presence of primary aliphatic alcohol functional group originated from PLGA segments which consist of methene, methyl and methane proton. 9 Alphatic carbonate ester groups also originated from PLGA through the formation of ester linkages between PLGA monomers that resulted in the generation of aliphatic polyester. 37 The aliphatic hydrocarbons demonstrate repeated units of PEI polymer, indicating the presence of PEI polymeric particulate within the DPAP system. 38 Layer-by-layer zeta potential characterization of DPAP particulate system Zeta potential is an important parameter to investigate the stability of a colloidal particulate formulation. Based on the data obtained from DLS analysis in Figure 12 , the naked BSA protein was highly electronegative with a zeta potential of 211 mV. After encapsulation with PLGA, the zeta potential of DP particles charged to 210.2 mV, demonstrating that PLGA electro-potential activity is largely neutral, hence, conferred no significant alteration to the electronegativity of BSA. The zeta potential of DP increased to 14.21 mV after surface charge modification with EDC/NHS at pH 2.7. This surface modification strategy enabled effective conjugation of aptamer molecules onto the DP particles by neutralizing additional negatively charged surface moieties resulting from the conjugation of carboxylic groups to the terminal end of PLGA. 11 With the introduction of the aptamer, the zeta potential decreased from 14.21 mV to 28.39 mV, indicating effective conjugation of the aptamer onto the surface of DP particles to form a negatively charge DPA system. The surface charge of the final DPAP formulation became positively charged with a zeta potential of 10.82 mV after complexation with the outer most layer made of hydrophilic PEI intercalated into the aptamer anchors. With the aptamer intercalated within the outer PEI molecular complex, electrostatic repulsive forces between the aptamer and the target cell membrane surface can be reduced significantly to facilitate improved target cell interactions, membrane permeation and endocytosis. DPAP formulation represents a molecularly engineered multifunctional particulate system consisting of a targeting element (an aptamer), active protein drug molecules, and a positively charged outer layer to enhance electrostatic interactions with negatively charged target cells and thus, improve targeted drug delivery. DPAP formulation is a co-polymeric (PLGA and PEI) system harboring DNA aptamer and BSA molecules in different compartments. The co-polymeric nature of DPAP endows it with multifunctional features for enhanced drug encapsulation, site targeting, and drug release. This makes it superior to other existing single polymer formulations in term of size, zeta potential colloidal particulate size and charge stability, cell transfection, drug and DNA aptamer payload capacity, and drug release profile. PLGA is highly recommended as pharmaceutical delivery carrier due to its high drug encapsulation efficiency; modifiable particle size to harbor molecules of different sizes; FDA-approved clinical safety; and pHsensitive endosomal degradation. Polycationic PEI is a wellknown nonviral transfection agent that entraps and condenses negatively charged aptamer to reduce target cell membrane electrostatic repulsions, leading to enhanced drug uptake into target cells for better therapeutic indices. The proton sponge effect of PEI facilitates endosomal release of entrapped content into cytosol and delivers drugs toward nucleus via active transport. 39 The presence of PEI polymeric layer helps to overcome initial burst release of BSA-encapsulated PLGA for prolonged drug release. Subramanian et al. reported the use of PEI as an efficient gene carrier to reduce tumor cell proliferation due to its capability in DNA condensation, nonmutagenic feature, low systemic cytotoxicity and good transfection efficiency at low concentrations.
Effect of pH on the biophysical characteristics of DPAP formulation
The isoelectric point (pI) of the DPAP particulate formulation, determined using DLS analysis, was pH 5.59, indicating that both the structure and functionality of DPAP formulation can easily be engineered for controlled drug release applications via pH-induced degradation under in vivo physiological conditions in mammalian systems. Thus, the DPAP formulation shows potential as a multifunctional particulate vehicle for controlled release of drug molecules to targeted sites. Figure 10 generally shows decreasing zeta potential of DPAP from 14.72 to 25.94 mV with increasing pH. However, at pH 7, the DPAP particles demonstrated a positive surface charge with a zeta potential of 10.82 mV. The positive zeta potential is necessary to facilitate targeted cell adhesion and intracellular uptake for delivering sufficient drug dosage to relevant sites under in vivo conditions. The study further demonstrated that higher pH conditions significantly reduce the surface charge of DPAP, making it more electronegative. The presence of OH -ions enables interactions with H 1 ions of DPAP particles in a neutralization process called deprotonation. The loss of H 1 ions increases the electronegativity of DPAP particulate formulation. At pH 7, the surface charge of DPAP particles remained unchanged since no excess OH -ions were present to trigger deprotonation. The converse phenomenon explains why DPAP formulation demonstrated a positive surface charged at pH 3 and 4. The presence of excess H 1 ions under low pH conditions enables interactions with OH -ions of DPAP in a protonation process, resulting in the formation of positively charged DPAP particulate system. Figure 10 also shows that under extreme acidic and alkaline conditions, the average hydrodynamic size of DPAP particulate formulation displayed the lowest values of 519.2 nm, 324.2 nm, 559.1 nm at pH 3, 10 and 11 respectively. The presence of excess H 1 ions and OH -ions could induce surface charge alterations of DPAP particles, facilitating the cleavage of DPAP particulate bonding structure including covalent bonding, hydrogen bonding, electrostatic interaction, and Van der Waals interaction. The average hydrodynamic size of DPAP particles formulation was largely constant (685.6 -780.8 nm) over a pH range of 5-8, indicating the stability of DPAP formulation at neutral and near neutral pH conditions and this is particularly advantageous for in vivo applications. Table 2 summarizes the influence of pH on the D [4, 3] hydrodynamic size and zeta potential of encapsulated molecules and DPAP formulation.
Encapsulation efficiency and loading capacity of DPAP formulation
The encapsulation efficiency, drug-loading capacity and in vitro drug release characteristics of DPAP particulate formulation were investigated using UV spectrophotometric analysis. The experimental results showed that BSA was encapsulated into PLGA particles with an encapsulation efficiency of 89.4 6 3.6% and a loading capacity of 0.179 6 0.007 mg BSA protein per mg PLGA. The DPAP formulation also demonstrated effective conjugation of thrombin-specific DNA aptamer in the range of 65% to 75%. This result is in keeping with reported encapsulation efficiencies for other functional polymeric formulations. 10, 13, 35 The study by Nyugen et al. generated POE-PEI microspheres via a modified double emulsion (w/o/w) approach and obtained an encapsulation efficiency of 60-70% of entrapped DNA plasmid molecules. Alibolandi et al. developed EpCAM aptamer conjugated PEG-PLGA nanoparticles via EDC/NHS coupling and pH gradient. They also demonstrated a comparable encapsulation efficiency of 91.25 6 4.27% of entrapped doxorubicin drug to target breast adenocarcinoma. The DPAP formulation showed a higher encapsulation efficiency than result reported by Aravind et al. They synthesized AS1411 aptamer-Paclitaxel-PLGA-lecithin-PEG nanoparticles and obtained an encapsulation efficiency of 60.76 6 3.4% using a nanoprecipitation synthesis technique. The result indicates that DPAP formulation is capable of shielding a significant load of DNA aptamer molecules from endonuclease degradation and rapid renal filtration thus retaining a sufficient quantity for targeted therapeutic activity. The effective encapsulation can be attributed to strong electrostatic interactions between PEI and DNA aptamer molecules to form PEI-DNA complexes. DPAP formulation demonstrated high encapsulation efficiencies for both BSA and thrombin-specific DNA aptamer under in vitro physiological conditions using isotonic PBS buffer with ionic strength and osmolarity similar to mammalian systems at pH 7.4. This is important to deliver sufficient amounts of intact aptamer molecules to bind onto their specific surface biomarkers or receptors at desired target sites to trigger endocytosis, leading to cellular uptake of drugs. Wellencapsulated aptamers can be protected from endonuclease attack and kidney filtration to maintain their functionality in the mammalian system. The high BSA efficiency of DPAP formulation demonstrates its ability to prevent drug leakage to nonspecific cells and carry sufficient drug load enough to elicit therapeutic effects at specific sites. The encapsulation efficiency of a polymeric formulation is highly influenced by physicochemical factors including pH, ionic strength, temperature, mechanical impacts and changes in size or shape. 32 The data for DPAP zeta potential showed the effects of protonation and deprotonation on the surface charge and size of DPAP, which are key drivers of polymer hydrolysis and degradations. Thus, DPAP was synthesized to allow for high encapsulation efficiency whilst enabling controlled polymer degradation under isotonic PBS buffer conditions at pH 7.4 to mimics the human circulatory system. Double emulsion with solvent evaporation integrated with short periods of sonication was used for DPAP synthesis to reduce mechanical impacts and produce reduced particle size with spherical shape for high drug encapsulation. The ratio of BSA:PLGA used was 1:10 as this ratio has been demonstrated to produce high encapsulation efficiencies. 40 The MTS cytotoxicity analysis of DPAP formulation
The cytotoxic effect of DPAP formulation on cell viability was investigated by MTS cytotoxicity assay using V79B cells. V79B cells were treated with six different concentrations of DPAP formulation in the range of 0.156 mL/mL to 5 mL/mL. IC 50 is a measure of the concentration of DPAP formulation needed to inhibit V79B cell growth by half. Results demonstrated no detection of IC 50 for all DPAP dosage levels, and the highest dosage of 5 mL/mL showed a cell viability of > 70% as shown in Table 3 . Hence, the DPAP formulation did not cause any prohibitive cytotoxic effect in all 6 concentrations based on the cell viability studies under in vitro condition.
Drug release profile of DPAP formulation
The in vitro drug release characteristics of DPAP formulation was studied in PBS buffer at pH 7.4, temperature 378C, and 120 rpm shaking. The result in Figure 11 shows the release kinetics of DPAP particulate formulation is in three phases. There was no initial burst release after first 24 h, indicating the multifunctional DPAP formulation is capable of retaining high drug dosage by preventing free diffusion or escape of drug molecules. This represents an effective initial pharmacokinetic behavior. The incorporation of PLGA and PEI into various sections of the molecular architecture of DPAP particulate formulation provided a slow initial drug release characteristics, resulting from initial degradative hydrolysis of intercalated PEI under physiological buffer conditions. The first release phase (day 1 to day 11) was attributed to the release of BSA molecules poorly entrapped or near the surface of the microsphere. The continuing slow release phase was due to chemomolecular diffusion of drug through the boundary layers of the DPAP polymeric matrix and DPAP-buffer interface into the physiological medium. The third release phase, starting from Day 38, demonstrated a higher kinetic rate of drug release due to enhanced degradative hydrolysis of DPAP microspheres, releasing more of the encapsulated drug from its microenvironment in the PLGA core into the physiological medium. The pharmacokinetics of DPAP microparticles is characterized to have a delayed and slow release profile with a controlled and small amount of BSA released each day. The tightly controlled release profile is due to the intercalation of PEI polymeric particles, acting as an additional shield and retaining drug molecules more efficiently within the DPAP particulate system as well as preventing the diffusion of water into the PLGA core. Consequently, the degradative hydrolysis rate of PLGA is reduced, leading to slow and controlled drug release characteristics. Compared to other research studies, the encapsulation efficiency and loading capacity of DPAP particulate delivery system show better payloads with a drug loading efficiency of 89 6 3.6%. Some previously reported encapsulation efficiencies include POE-PEI microparticles (65-75%), 35 AS1411-PEG-PLGA nanoparticles (44.7 6 3.9%), 14 MUC1-chitosan nanoparticles (7.1%), 15 and AS1411 aptamer-Paclitaxel-PLGA-lecithin-PEG nanoparticulate system (60.76 6 3.4%). 13 This finding demonstrates the capacity of of DPAP formulation to harbor and transport optimal drug dosages critical for effective therapeutic treatment to targeted sites. The outermost surface of DPAP formulation is positively charged to minimize electrostatic repulsions with negatively charged membrane surface of targeted cell for enhanced transfection and cellular uptake. 1, 7 The drug release profile of DPAP showed a controlled release characteristics over a period of time. This indicates that DPAP formulation can engineered as delivery vehicles to provide extended shielding of encapsulated active ingredients using double layered PLGA and PEI system. All these findings show promise for DPAP as a targeted drug delivery carrier, and represent a major contribution to research efforts toward developing new and improved strategies for targeted drug delivery. These in vitro investigations are critical in setting the essential parameters required for the synthesis of DPAP particulate system with effective hydrodynamic size and surface charge characteristics as well as physiological conditions essential to optimize the potentials of DPAP as a targeted drug carrier. This is critical in preparation for the next phase of research in terms of in vivo validation of DPAP in cells and animals.
Conclusion
We have demonstrated preliminary work covering the design, synthesis, and characterization of a multifunctional targeted drug delivery system made of aptamer-conjugated BSA-loaded PLGA-PEI particles. Negatively charged aptamer molecules were successfully conjugated onto positively charged BSAloaded PLGA particles and PEI particles was used to intercalate the negatively charged aptamer-linked BSA-PLGA particles surface to effectively produce DPAP formulation with tailored positive surface charge and D [4, 3] average hydrodynamic size. Physicochemical characterizations, cytotoxicity analysis and in vitro release test of the DPAP particulate formulation demonstrate a great potential as a multifunctional polymeric vehicle for targeting and delivering sufficient drug dosage to specific cell with sustained and controlled drug release profile. DPAP particulate structure could also be engineered to host multiple drugs and aptamers in unique sections of the system architecture to target multiple disease sites. Notwithstanding, further in vivo studies are essential in cells and mouse models to completely characterize the capabilities of DPAP formulation for enhanced targeting and delivering of drug molecules specific sites.
